Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Tag archive for ‘tedizolid’

Cubist Pharmaceuticals: An Overview Based on a Recent Company Presentation (CBST, No Opinion)

Introduction I recently was invited to attend a broker sponsored conference for biotechnology companies. Altogether, there were 116 companies presenting at the conference and I attended 29 individual company presentations. I regularly attend conferences like this to screen for potential new companies to cover and to get updates on companies that I already have done […]

Trius Therapeutics to be Acquired by Cubist (TSRX: $13.66)

Implications for Trius Shareholders Cubist Pharmaceuticals (CBST) and Trius Therapeutics, Inc. (TSRX) announced that they have signed a definitive agreement under which Cubist will acquire all outstanding shares of Trius for $13.50 per share in cash. In addition, Trius shareholders will receive a Contingent Value Right that entitles Trius shareholders to receive up to $2.00 […]

Thoughts on the Growing Crisis of Bacterial Resistance to Antibiotics

Investment Overview We hear constantly from the media about problems with bacterial resistance to antibiotics. I think that this is an indication that we have reached the point at which society will collectively decide to declare a war on resistant bacteria that could provide the same impetus to the development of anti-microbial drugs that the […]

Settlement Between Pfizer and Teva on Generic Zyvox is a Significant Positive for Trius Therapeutics

The Issue On May 31, 2012, Pfizer Inc. (PFE) and Teva (TEVA reached a settlement that licenses to Teva a generic version of Pfizer’s antibiotic Zyvox (linezolid). Pfizer first sued Teva in January 2010 for patent infringement after Teva informed Pfizer that it had filed an abbreviated new drug application with the FDA.This was done […]

An Update on Trius Therapeutics’ Tedizolid; a Potential Blockbuster for Treating MRSA Infections (TSRX, $5.41)

  I am reiterating my buy recommendation on Trius Therapeutics (NASDAQ: TSRX). This note is follow-up to a 35 page report called “Trius Therapeutics’ Tedizolid has Blockbuster Potential for MRSA Infections” which was issued on May 30, 2012 when Trius closed at a price of $5.01. I laid out my thinking on why I thought […]

Trius’ (TSRX) Tedizolid Has Blockbuster Potential for MRSA Infections

Trius Therapeutics TSRX) is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that have increased to epidemic levels in both the hospital and community settings. There are a number of companies competing in this market and a host of new products in development, but I see tedizolid as […]